Questions & explanations
1. Compare how checkpoint inhibitors and targeted therapy attack cancer cells.
Checkpoint inhibitors work by boosting the immune system to kill cancer cells, while targeted therapy directly blocks cancer growth pathways. Checkpoint inhibitors do not target cancer cells themselves but remove brakes on T-cells, which then attack any cancer cell they recognize. Targeted therapy only works if the cancer has a specific molecular target. Checkpoint inhibitors can cause immune-related side effects like inflammation in organs, while targeted therapy often has different side effects like rash or diarrhea. Resistance mechanisms also differ: checkpoint inhibitors fail when tumors hide from T-cells, while targeted therapy fails when cancer cells change the target.
2. What is the main goal of personalized medicine?
Personalized medicine aims to tailor medical treatment to each patient's unique genes, environment, and lifestyle. Instead of a one-size-fits-all approach, doctors use information like genetic tests to choose the safest and most effective drug for that person. For example, in cancer treatment, a tumor's genetic profile can show which targeted therapy will work best. This reduces trial-and-error prescribing and lowers the risk of side effects. Stratified therapeutics is a related idea where patients are grouped into subgroups based on shared biomarkers, such as a specific gene mutation. Both approaches help give the right drug to the right patient at the right dose.
3. How does Schild analysis determine the affinity of a competitive antagonist?
Schild analysis is used to measure the affinity (pA2) of a competitive antagonist. It involves constructing dose-response curves for an agonist in the presence of increasing concentrations of the antagonist. A competitive antagonist shifts the curve to the right without changing the maximal response. The ratio of agonist concentrations needed to produce half-maximal response in the presence vs. absence of antagonist (dose ratio) is calculated. Plotting log(dose ratio - 1) against log(antagonist concentration) gives a straight line with slope 1; the intercept on the x-axis is the pA2, which equals the negative log of the antagonist dissociation constant (K_B).
4. What is a multi-compartment model in pharmacokinetics?
A multi-compartment model divides the body into two or more connected spaces, or compartments, to describe drug movement. The central compartment usually includes blood and well-perfused organs, while peripheral compartments represent tissues where drug distributes more slowly. This model explains why drug concentration in blood declines in two or more phases: a rapid distribution phase followed by a slower elimination phase. For example, after an IV bolus, the drug first enters the central compartment, then distributes to peripheral tissues, and finally is eliminated. Multi-compartment models are more accurate than one-compartment models for many drugs.
5. Give an example of biased agonism involving β-arrestin and G protein pathways.
A well-known example is at the angiotensin II type 1 receptor (AT1R). The natural hormone angiotensin II activates both G protein signaling (leading to vasoconstriction) and β-arrestin recruitment (which can promote cell growth). Some biased agonists, like TRV027, preferentially activate β-arrestin over G protein. This can produce beneficial effects like heart contractility without the harmful vasoconstriction. Another example is at the mu-opioid receptor: some ligands like TRV130 (oliceridine) are biased toward G protein signaling and away from β-arrestin, potentially providing pain relief with less respiratory depression and constipation.
6. What are the therapeutic implications of biased agonism?
Biased agonism offers the potential to develop drugs that separate desired therapeutic effects from side effects. For example, at the mu-opioid receptor, G protein signaling mediates pain relief, while β-arrestin recruitment is linked to respiratory depression and tolerance. A G protein-biased agonist could provide effective pain relief with reduced side effects. Similarly, at the angiotensin receptor, β-arrestin-biased agonists may treat heart failure without causing vasoconstriction. Biased agonism also helps understand receptor biology and may lead to personalized medicine, as different patients may have different pathway sensitivities.
7. How does the concept of biased agonism challenge the traditional view of receptor activation?
Traditionally, receptors were thought to exist in only two states: inactive and active. An agonist stabilized the active state, activating all downstream pathways equally. Biased agonism shows that receptors can adopt multiple active conformations, each favoring different signaling partners. This challenges the simple two-state model and supports a multi-state model where different ligands stabilize distinct conformations. It also means that efficacy is not a single property but can be pathway-specific. This has led to new drug discovery strategies focusing on pathway-selective ligands rather than just overall agonists or antagonists.
8. Compare how infections are managed in immunocompromised versus immunocompetent patients.
In immunocompromised patients, infections are more severe and can spread quickly, so treatment starts earlier and with stronger antibiotics. For example, a simple urinary tract infection in a healthy person may be treated with oral antibiotics, but in a transplant patient, it may require intravenous broad-spectrum drugs. Also, immunocompromised patients often need longer treatment courses and may require combination therapy to cover resistant germs. In contrast, immunocompetent patients can often clear infections with narrow-spectrum antibiotics. Prophylaxis is also common in immunocompromised patients but not in healthy individuals.
9. What does bioavailability mean for a drug?
Bioavailability (F) is the fraction of a drug that reaches the bloodstream unchanged after administration. It is important because only the drug in blood can reach its target. For example, if you take a pill, the drug must be absorbed from the gut into the blood. If the liver breaks down some of it before it reaches the rest of the body, the bioavailability is less than 100%. Factors that affect bioavailability include how the drug is given (oral vs. injection), how well it dissolves, and how much is broken down in the gut or liver. A drug given by injection usually has 100% bioavailability because it goes directly into the blood.
10. How can the Cheng-Prusoff equation be applied to estimate Ki from an IC50 obtained in a functional assay?
The Cheng-Prusoff equation is originally for binding assays, but it can be adapted for functional assays if certain conditions hold. In a functional assay, the IC50 for an antagonist is the concentration that reduces the agonist response by half. To estimate Ki, one uses the equation: Ki = IC50 / (1 + [A]/EC50), where [A] is the agonist concentration and EC50 is its half-maximal effective concentration. This correction accounts for the agonist's concentration and potency. However, this assumes the antagonist is competitive and the response is linear with occupancy. The resulting Ki approximates the antagonist's binding affinity.
11. How can biased agonism be measured experimentally?
Biased agonism is measured by comparing the relative activation of different signaling pathways. For each pathway, a dose-response curve is generated, and parameters like Emax and EC50 are obtained. Then, a bias factor is calculated using methods like the operational model (Black/Leff) to quantify the relative efficacy of the ligand for each pathway. Common assays include measuring G protein activation (e.g., GTPγS binding) and β-arrestin recruitment (e.g., BRET or Tango assays). The bias factor compares the ligand's activity to a reference agonist (often the endogenous ligand). A significant difference indicates biased agonism.
12. How do enzyme-linked receptors differ from G protein-coupled receptors in signaling?
Enzyme-linked receptors have their own enzyme activity or are directly linked to enzymes, while G protein-coupled receptors (GPCRs) use separate G proteins to start signals. RTKs phosphorylate proteins directly, whereas GPCRs activate G proteins that then affect other enzymes. Enzyme-linked receptors often lead to longer-lasting effects like changes in gene expression, while GPCR signals are usually faster and shorter. Both types can use second messengers, but enzyme-linked receptors often involve phosphorylation cascades. They also typically respond to growth factors and hormones, while GPCRs respond to many different signals.